Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,310 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis;Inflammatory Clear all
Terminated Phase 4 Interventional

Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System

NCT00546598
View directory record Official record
Conditions
Non-inflammatory Joint Disease, Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Post-traumatic Arthritis
Interventions
Total hip replacement/arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
21 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Springfield, Illinois • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 24, 2026, 4:22 AM EDT
Recruiting Not applicable Interventional

Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)

NCT04949087
View directory record Official record
Conditions
Arthritis Shoulder
Interventions
Glenohumeral Injection
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 3 Interventional

Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA

NCT00570934
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Cholecalciferol, Calcium, Calcium and cholecalciferol, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 24, 2026, 4:22 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Fullerton, California • Los Alamitos, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 24, 2026, 4:22 AM EDT
Completed No phase listed Observational

An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)

NCT01338545
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 1Phase 2 Interventional

Gait Retraining to Reduce Knee Osteoarthritis Pain

NCT01397981
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Gait retraining
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Patient and Provider Interventions for Managing Osteoarthritis in Primary Care

NCT01435109
View directory record Official record
Conditions
Osteoarthritis
Interventions
Patient Behavioral Intervention for OA, Provider Intervention for OA, Combined Patient and Provider Interventions for OA
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

NCT03691844
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
AMZ001, Placebo, Comparator
Drug
Lead sponsor
Amzell
Industry
Eligibility
40 Years to 85 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Milford, Connecticut • The Villages, Florida • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

NCT00856544
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
46
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Jul 24, 2026, 4:22 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
Interventions
Resiniferatoxin, Zilretta, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
La Mesa, California • Pasadena, California • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ASP5094, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)

NCT04533711
View directory record Official record
Conditions
Osteoarthritis
Interventions
OA-PCP Intervention, Attention Control
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 24, 2026, 4:22 AM EDT
Terminated Phase 4 Interventional Results available

Non-cancer Pain and Cognitive Impairment: A Disabling Relationship

NCT01264965
View directory record Official record
Conditions
Arthritis, Pain, Cognitive Impairment
Interventions
long acting oxycodone, extra strength acetaminophen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 69 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Covina, California • Upland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Knee Biofeedback Rehabilitation Interface for Game-based Home Therapy for Patients With Knee Osteoarthritis

NCT04187092
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
KneeBright Group, Standard Rehabilitation group
Other
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NSAID Drug Interaction Study

NCT01884272
View directory record Official record
Conditions
Gout
Interventions
lesinurad 400 mg, naproxen 250 mg, indomethacin 25 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional

Anterior Referencing Versus Posterior Referencing in Minimally Invasive Total Knee Arthroplasty

NCT01135030
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total knee
Procedure
Lead sponsor
Heekin Orthopedic Research Institute
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2012 · Synced Jul 24, 2026, 4:22 AM EDT
Recruiting No phase listed Observational

AETOS Shoulder System

NCT06319911
View directory record Official record
Conditions
Shoulder Osteoarthritis, Shoulder Arthritis
Interventions
AETOS
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Columbus, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

NCT04762498
View directory record Official record
Conditions
Uncontrolled Gout, Chronic Gout
Interventions
Pegloticase, Methotrexate (MTX)
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 4 Interventional

Postoperative Pain and Analgesic Requirements After Preoperative Methadone for Primary TKA

NCT06691633
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Preoperative Methadone, Preoperative Oxycodone
Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 89 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Jul 24, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 24, 2026, 4:22 AM EDT